MeiraGTx Holdings plc

Aug 13, 2026

MeiraGTx Reports Second Quarter 2026 Financial and Operational Results

MeiraGTx announced its second quarter 2026 financial and operational results, highlighting the receipt of FDA Breakthrough Therapy Designation for AAV2-hAQP1. The company also reported encouraging three-year data from its Phase 1 AQUAx clinical trial, which evaluates AAV2-hAQP1 for treating moderate to severe radiation-induced xerostomia. Additionally, MeiraGTx completed the acquisition of all interests and rights related to this treatment.

Aug 6, 2026

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MeiraGTx Holdings plc has announced the approval of equity awards by its Compensation Committee under Nasdaq Listing Rule 5635(c)(4). This decision reflects the company's strategy to incentivize its employees as it continues to develop its genetic medicines. The equity awards are part of the company's broader efforts to align employee interests with shareholder value.

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx has announced a strategic investment of $400 million from Oberland Capital, which includes $375 million in non-dilutive cash and $25 million in equity. This funding aims to support the development and commercialization of AAV2-hAQP1, a treatment for late radiation-induced xerostomia. Following regulatory approval, Oberland Capital will receive capped royalties on net sales of the product.

May 14, 2026

MeiraGTx Reports First Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 - Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the

MeiraGTx Holdings plc reported strong financial and operational results for the first quarter of 2026, highlighted by the FDA granting Breakthrough Therapy Designation for AAV2-hAQP1, which has shown positive three-year data in treating late radiation-induced xerostomia. The company also announced a strategic asset acquisition of bota-vec for X-linked retinitis pigmentosa, further enriching its therapeutic portfolio. Financially, MeiraGTx strengthened its position with a $100 million funding increase, enabling continued development and potential regulatory submissions across multiple regions for both therapies.

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) - Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acq

MeiraGTx Holdings plc has announced the acquisition of botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for treating X-linked retinitis pigmentosa (XLRP). MeiraGTx plans to expedite regulatory filings for bota-vec in the U.S., EU, and Japan, aiming for a potential market launch in 2027. The Phase 3 LUMEOS study indicated significant improvements in vision metrics among participants. The acquisition involves a $25 million upfront payment with further financial commitments tied to regulatory and sales milestones.

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia - Clinically meaningful improvements in xerostomia symptoms

MeiraGTx announced positive three-year data from the Phase 1 AQUAx clinical trial for AAV-hAQP1, targeting late radiation-induced xerostomia. The study demonstrated sustained improvements in symptoms and saliva flow for both bilateral and unilateral treatment groups up to three years post-administration. AAV-hAQP1 has been shown to be safe and well-tolerated, contributing to its potential as a transformative treatment for a condition with significant unmet medical needs.

Mar 26, 2026

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational R

MeiraGTx has received FDA Breakthrough Therapy Designation for its AAV2-hAQP1 treatment targeting Grade 2 and Grade 3 radiation-induced xerostomia. Supported by three years of clinical data, this designation is expected to accelerate development efforts. The company also reported its financial results for 2025, highlighting a strategic collaboration with Eli Lilly and a partnership with Hologen AI to optimize clinical data analysis. Despite receiving a boost in potential revenue from collaborations, MeiraGTx faces challenges with increased operating expenses and a decline in service revenue.

Nov 13, 2025

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results - Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rig

MeiraGTx Holdings plc reported its third-quarter results for 2025, highlighting a strategic collaboration with Eli Lilly to develop genetic medicines in ophthalmology. The partnership includes exclusive rights to AAV-AIPL1 for treating Leber congenital amaurosis 4, backed by promising data showing vision restoration in children. Financially, cash reserves decreased significantly year-over-year, alongside a notable decline in service revenue, raising concerns about operational performance. However, advancements in clinical trials for various programs indicate that the company remains focused on expanding its impactful gene therapy pipeline.

Nov 10, 2025

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology LONDON and

MeiraGTx Holdings plc has announced a strategic collaboration with Eli Lilly and Company to develop and commercialize genetic medicines specifically targeting ophthalmology. Under this partnership, Lilly will gain exclusive rights to MeiraGTx's AAV-AIPL1 program, which has demonstrated remarkable success in restoring vision in children affected by Leber congenital amaurosis 4. Additionally, the collaboration includes access to MeiraGTx's other innovative gene therapy technologies, allowing both companies to expedite the delivery of transformational treatments for severe eye diseases. MeiraGTx will receive an initial payment of $75 million along with potential milestone payments exceeding $400 million.

Aug 14, 2025

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results - Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal stu

MeiraGTx Holdings plc has reported positive financial and operational outcomes for Q2 2025, demonstrating progress in several pivotal clinical programs. The company has secured alignment with the FDA for the Phase 2 study of AAV-hAQP1 aimed at treating radiation-induced xerostomia, potentially leading to a Biologics License Application in the future. Additionally, the FDA has granted RMAT designation for AAV-GAD, signaling a promising trajectory for its Parkinson's disease treatment. The announcement included updates on the company's collaborations and clinical advancements, positioning MeiraGTx for future regulatory approvals and potentially significant market opportunities.

MeiraGTx Reports First Quarter 2025 Financial and Operational Results - Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, H

MeiraGTx Holdings plc announced its first-quarter 2025 financial results, highlighting a strategic collaboration with Hologen AI that includes a $200 million upfront payment and a joint venture aimed at accelerating the development of AAV-GAD for Parkinson's disease. The FDA granted RMAT designation for this therapy, potentially expediting its approval process. Additionally, encouraging efficacy data for rAAV8.hRKp.AIPL1 was published, supporting an application for marketing authorization based on positive treatment responses in children with LCA4. The company reported sufficient capital to support operations into 2027, bolstering its financial position.

May 9, 2025

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease - This RMAT designation is based on data from 3 clinical studies demonstrating the poten

MeiraGTx Holdings plc announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational gene therapy AAV-GAD for treating Parkinson's disease. This designation was based on data from three clinical studies demonstrating clinically meaningful benefits in patients inadequately managed by current medications. AAV-GAD aims to restore normal brain activity through a one-time infusion procedure. The company expressed optimism about working closely with the FDA to further develop this potential treatment.

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process - MeiraGTx to receive $200

MeiraGTx has entered a strategic collaboration with Hologen AI to accelerate the Phase 3 development of its AAV-GAD treatment for Parkinson's disease. As part of this partnership, MeiraGTx will receive $200 million in upfront cash and Hologen AI will contribute an additional $230 million for the project's completion. The joint venture, Hologen Neuro AI Ltd, will utilize advanced AI technologies to enhance drug development for neurological disorders. This collaboration significantly strengthens MeiraGTx's financial position and expands its clinical development capabilities.

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia - RMAT designation recognizes the preliminary clinical evidence of

MeiraGTx Holdings plc has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy AAV2-hAQP1, aimed at treating Grade 2/3 radiation-induced xerostomia. This designation highlights the therapy's potential benefits and allows for expedited regulatory privileges, including increased interaction with the FDA. The treatment addresses a significant unmet need, as patients suffering from xerostomia due to radiation treatment currently have no alternative options. The RMAT designation is expected to fast-track the development and review of AAV2-hAQP1, promoting accessibility to this promising therapy for patients.

MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates - Received 3 Rare Pediatric Disease Designations (RPDD) from FDA for each of 3 potential therapies for 3 different rare

MeiraGTx Holdings plc reported its financial and operational results for Q3 2024, announcing significant advancements, including the receipt of three Rare Pediatric Disease Designations from the FDA for its therapies targeting inherited retinal diseases. The company plans to submit a Marketing Authorization Application in the UK for its AAV-AIPL1 program without further clinical studies. Positive data from a Parkinson's disease treatment study supports the initiation of a Phase 3 study. These developments underscore the company's potential to deliver transformative treatments for rare pediatric disorders more rapidly.

Oct 15, 2024

▲ +14.9%on this news· ran to +32% by day 3

MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease The primary study objective of safety and tolerability was met Significant and

MeiraGTx Holdings plc reported positive results from their clinical bridging study of AAV-GAD for Parkinson's disease, achieving key safety and tolerability objectives. The study showed significant improvements in key efficacy endpoints, including an 18-point increase in the Unified Parkinson's Disease Rating Scale among high-dose participants. Additionally, both high and low-dose groups demonstrated notable enhancements in quality of life metrics. These outcomes suggest that AAV-GAD has the potential to improve treatment for Parkinson's patients, supporting future regulatory discussions for Phase 3 trials.

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results - Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX

MeiraGTx Holdings plc announced a $50 million offering of ordinary shares led by Sanofi to support its financial needs for upcoming clinical developments. The offering is accompanied by positive data from the Phase 1 AQUAx study for radiation-induced xerostomia (RIX), indicating improvements in patient-reported outcomes. Additionally, the company secured an Innovation Passport Designation for a treatment aimed at AIPL1-Leber congenital amaurosis 4 (LCA4), allowing expedited access in the UK. Despite these advances, the company reported an increased net loss of $48.6 million for the second quarter of 2024, raising concerns regarding its financial sustainability.

May 9, 2024

MeiraGTx Reports First Quarter 2024 Financial and Operational Results - Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medici

MeiraGTx Holdings plc reported positive financial and operational results for Q1 2024, showcasing encouraging data from the Phase 1 AQUAx study aimed at treating radiation-induced xerostomia. The company received a $50 million milestone related to its Phase 3 LUMEOS clinical trial for treatment of X-linked retinitis pigmentosa. They confirmed that clinical timeline commitments remain on track for multiple programs, including therapies for Parkinson's disease and xerostomia. Financially, MeiraGTx holds significant liquidity to support operations through the first quarter of 2026.

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates - Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiatio

MeiraGTx Holdings plc reported strong financial and operational results for Q4 and the full year of 2023, highlighting advancements in their clinical programs. The company has aligned with the FDA on requirements for its Phase 2 AQUAx2 clinical trial for radiation-induced xerostomia, paving the way for potential regulatory approval. Additionally, the treatment for children with the rare LCA4 condition has shown significant improvements in vision, indicating the effectiveness of their AAV-AIPL1 gene therapy. MeiraGTx continues to develop its manufacturing capabilities and expand its partnerships in the biopharmaceutical sector.

MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals - MeiraGTx to receive $50 million milestone after initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvov

MeiraGTx Holdings plc has announced the achievement of a $50 million milestone from Janssen Pharmaceuticals after the initiation of the LUMEOS extension study for the Phase 3 clinical trials of botaretigene sparoparvovec. This milestone was triggered under an asset purchase agreement related to the treatment of X-linked retinitis pigmentosa. The announcement highlights the company's advanced capabilities in gene therapy and its focus on addressing significant unmet medical needs. The achievement is expected to provide a boost to MeiraGTx's financial position as it continues its clinical development efforts.

Dec 21, 2023

▲ +32.6%on this news· ran to +45% by day 3

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million - MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPG

MeiraGTx Holdings plc has announced an asset purchase agreement with Janssen Pharmaceuticals for the remaining interests in its gene therapy bota-vec, potentially worth up to $415 million. The deal includes an upfront payment of $130 million along with milestone payments and aims to enhance MeiraGTx's financial stability. The company plans to use the additional capital to focus on its late-stage clinical programs and accelerate development in various therapeutic areas. This strategic move positions MeiraGTx strongly in the gene therapy market.

Nov 14, 2023

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results - Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 -

MeiraGTx Holdings plc announced its financial results for Q3 2023, highlighting a $30 million strategic investment from Sanofi and ongoing enrollment in a Phase 2 study for Xerostomia treatment. The company sees this investment as validation of its gene therapy approach for larger chronic diseases. Despite the positive developments, financial reports reveal an increased net loss compared to the previous year and rising research and development expenses. Overall, MeiraGTx is positioned for future growth with a robust pipeline and strong financial backing.

Oct 30, 2023

▲ +20.3%on this news· ran to +35% by day 3

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities - Sanofi to purchase $30 million of ordinary shares of the Company at a price of $7.50 per sha

MeiraGTx Holdings plc has announced a $30 million strategic investment from Sanofi, purchasing 4 million ordinary shares at $7.50 per share. This investment underscores Sanofi's confidence in MeiraGTx's Riboswitch gene regulation technology and its clinical programs. The company aims to explore further strategic opportunities, working with financial and legal advisors to maximize shareholder value. CEO Alexandria Forbes emphasized the potential of their vertically integrated gene therapy platform, while Sanofi expressed a commitment to innovative solutions for treating patients.

Aug 10, 2023

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results - Phase 3 LUMEOS clinical trial of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP)

MeiraGTx Holdings plc reported its financial and operational results for Q2 2023, highlighting advancements in their clinical programs and technologies. The positive outcomes in the completed AQUAx Phase 1 study and ongoing Phase 3 LUMEOS trial for bota-vec are notable. The company has also secured a commercial QC testing license for its manufacturing facility in Ireland, allowing it to expand its operational capabilities. However, the company experienced a decrease in license revenue and an increase in expenses, which could pose financial challenges.

MeiraGTx Reports First Quarter 2023 Financial and Operational Results - Raised approximately $60 million in a private placement in May 2023 with investors consisting of several of the Company's top shareholders - On trac

MeiraGTx Holdings plc reported encouraging financial and operational results for the first quarter of 2023, reflecting advancements in several clinical-stage programs. The company raised approximately $60 million through a private placement to bolster its pipeline. Notably, the pivotal Lumeos Phase 3 study is advancing well and is expected to support a BLA filing in 2024. However, the company also reported a net loss of $30.4 million for the quarter, alongside decreased license revenues and rising administrative costs.

Mar 14, 2023

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results - Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3 Radiation-Induced Xerostomia in Decemb

MeiraGTx Holdings plc reported its fourth quarter and full-year results for 2022, highlighting positive clinical data from its AQUAx AAV-hAQP1 Phase 1 trial for radiation-induced xerostomia. The company also presented promising safety data and vision improvements for XLRP patients treated with botaretigene sparoparvovec. Furthermore, MeiraGTx is on track for a BLA submission in 2024, while facing an increased net loss attributable to ordinary shareholders. The report reflects both advancements in clinical programs and ongoing financial challenges.

Nov 10, 2022

MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc. -- Updated Positive Topline Data from the Phase 1/2 Trial of Botare

MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc. -- Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-link

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results -- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results -- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Financing Secured by Manufacturing Facilities Ex

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities - Credit facility is collateralized by MeiraGTx's wholly-owned manufacturing facilities in London

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities - Credit facility is collateralized by MeiraGTx's wholly-owned manufacturing facilities in London, UK and Shannon, Ireland - $75 million at closing strengt

May 12, 2022

MeiraGTx Reports First Quarter 2022 Financial and Operational Results - Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Pat

MeiraGTx Reports First Quarter 2022 Financial and Operational Results -Phase 3 Lumeos Clinical Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Actively Dosing Patients -Phase 1 AQUAx Study of AAV-hAQP1 for Radiation-Induc

Apr 27, 2022

MeiraGTx Appoints Debra Yu, MD to Board of Directors LONDON and

MeiraGTx Appoints Debra Yu, MD to Board of Directors LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directo

Mar 10, 2022

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results - Phase 3 Lumeos Clinical Trial of botaretigene sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Enro

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results - Phase 3 Lumeos Clinical Trial of botaretigene sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Enrolling and Dosing Patients - Received $30 Million Cash Mile

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia Clinically meaningful improvements in xerostomia symptoms and di

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia LONDON and NEW YORK, Dec. 7, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinic

Nov 10, 2021

MeiraGTx Reports Third Quarter 2021 Financial and Operational Results LONDON and

MeiraGTx Reports Third Quarter 2021 Financial and Operational Results LONDON and NEW YORK, November 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third qu

Aug 11, 2021

MeiraGTx Reports Second Quarter 2021 Financial and Operational Results LONDON and

MeiraGTx Reports Second Quarter 2021 Financial and Operational Results LONDON and NEW YORK, August 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second qu

May 11, 2021

MeiraGTx Reports First Quarter 2021 Financial and Operational Results LONDON and

MeiraGTx Reports First Quarter 2021 Financial and Operational Results LONDON and NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter

Mar 11, 2021

MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results - Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR - Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 P

MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results -Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR -Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia -Complet

Dec 17, 2020

MGTXConferences/Events

MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia -- Webcast and conference call to take place on

MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia -- Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET -- LONDON and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX),

Nov 13, 2020

MGTXConferences/Events

MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment Data presented at AAO 2020

MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retin

Nov 5, 2020

MeiraGTx Reports Third Quarter 2020 Financial Results - MeiraGTx preparing to initiate Phase 3 trial of AAV-RPGR - Plasmid production facility expected to be completed year-end 2020 LONDON and

MeiraGTx Reports Third Quarter 2020 Financial Results - MeiraGTx preparing to initiate Phase 3 trial of AAV-RPGR - Plasmid production facility expected to be completed year-end 2020 LONDON and NEW YORK, November 5, 2020 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically int

Oct 3, 2020

MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP) Data presented at EURETINA 2020 Virtual Congress show

MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP) LONDON and NEW YORK, October 3, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically inte

Aug 6, 2020

MeiraGTx Reports Second Quarter 2020 Financial Results - Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented - AAV-RPGR to advance into Phase 3 Lumeos clinical tri

MeiraGTx Reports Second Quarter 2020 Financial Results LONDON and NEW YORK, August 6, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June

Jul 17, 2020

MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients Data being presented at the American Society of Retin

Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting Significant impr

May 7, 2020

MeiraGTx Reports First Quarter 2020 Financial Results LONDON and

MeiraGTx Reports First Quarter 2020 Financial Results LONDON and NEW YORK, May 7, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31,

Mar 11, 2020

MeiraGTx Reports Full Year 2019 Financial Results LONDON and

MeiraGTx Reports Full Year 2019 Financial Results LONDON and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the full year ended December 31, 20

Nov 7, 2019

MeiraGTx Reports Third Quarter 2019 Financial Results LONDON and

MeiraGTx Reports Third Quarter 2019 Financial Results LONDON and NEW YORK, November 7, 2019 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended September 30,

Aug 7, 2019

MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update LONDON and

MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update LONDON and NEW YORK, August 7, 2019 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for th

May 14, 2019

MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update Positive 6-month results from Phase 1/2 clinical trial of AAV-RPE65 Enrollment completed in the Phase 1/2 clinical trial investigating A

MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update Positive 6-month results from Phase 1/2 clinical trial of Enrollment completed in the Phase 1/2 clinical trial investigating AAV-CNGB3 gene therapy for the treatment of achromatopsia LONDON and

May 10, 2019

MeiraGTx Appoints Nicole Seligman to Board of Directors LONDON and

MeiraGTx Appoints Nicole Seligman to Board of Directors LONDON and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Nicole Seligman to its Board of Direc

Mar 26, 2019

MeiraGTx Reports Full Year 2018 Financial Results LONDON and

MeiraGTx Reports Full Year 2018 LONDON and NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2018

Feb 27, 2019

MeiraGTx Announces $80 Million Private Placement of Ordinary Shares LONDON and

MeiraGTx Announces $80 Million Private Placement of Ordinary Shares LONDON and NEW YORK, February 27, 2019 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximatel

Feb 21, 2019

MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors LONDON and

MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors LONDON and NEW YORK, February 21, 2019 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Martin Indyk to its Boar

Jan 31, 2019

MGTXConferences/Events

MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases Conference call and webcast today

MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases Conference call and webcast today, January 31, 2019 at 8:30 a.m. EST MeiraGTx to receive $100 million cash upfront payment upon closing

Nov 8, 2018

MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update LONDON and

MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update LONDON and NEW YORK, Nov. 8, 2018 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the th

Oct 9, 2018

MeiraGTx Announces Acquisition of Vector Neurosciences, Gains Phase 2 Gene Therapy Program for Parkinson s Disease LONDON and

MeiraGTx Announces Acquisition of Vector Neurosciences, Gains Phase 2 Gene Therapy Program for Parkinson s Disease LONDON and NEW YORK, October 9, 2018 (GLOBE NEWSWIRE) MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today ann

Aug 8, 2018